400 related articles for article (PubMed ID: 23041121)
21. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.
Gyulai Z; Endresz V; Burian K; Pincus S; Toldy J; Cox WI; Meric C; Plotkin S; Gönczöl E; Berencsi K
J Infect Dis; 2000 May; 181(5):1537-46. PubMed ID: 10823751
[TBL] [Abstract][Full Text] [Related]
22. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
Gonczol E; Plotkin S
Expert Opin Biol Ther; 2001 May; 1(3):401-12. PubMed ID: 11727514
[TBL] [Abstract][Full Text] [Related]
23. A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.
McVoy MA; Lee R; Saccoccio FM; Hartikka J; Smith LR; Mahajan R; Wang JB; Cui X; Adler SP
Vaccine; 2015 Dec; 33(51):7328-7336. PubMed ID: 26597035
[TBL] [Abstract][Full Text] [Related]
24. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
[TBL] [Abstract][Full Text] [Related]
25. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice.
Wen Y; Monroe J; Linton C; Archer J; Beard CW; Barnett SW; Palladino G; Mason PW; Carfi A; Lilja AE
Vaccine; 2014 Jun; 32(30):3796-804. PubMed ID: 24837507
[TBL] [Abstract][Full Text] [Related]
26. Ad-gBCMVpoly: A novel chimeric vaccine strategy for human cytomegalovirus-associated diseases.
Zhong J; Khanna R
J Clin Virol; 2009 Dec; 46 Suppl 4():S68-72. PubMed ID: 19646921
[TBL] [Abstract][Full Text] [Related]
27. Cytomegalovirus Vaccines: Current Status and Future Prospects.
Anderholm KM; Bierle CJ; Schleiss MR
Drugs; 2016 Nov; 76(17):1625-1645. PubMed ID: 27882457
[TBL] [Abstract][Full Text] [Related]
28. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.
Wills MR; Carmichael AJ; Mynard K; Jin X; Weekes MP; Plachter B; Sissons JG
J Virol; 1996 Nov; 70(11):7569-79. PubMed ID: 8892876
[TBL] [Abstract][Full Text] [Related]
29. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.
Reap EA; Morris J; Dryga SA; Maughan M; Talarico T; Esch RE; Negri S; Burnett B; Graham A; Olmsted RA; Chulay JD
Vaccine; 2007 Oct; 25(42):7441-9. PubMed ID: 17870214
[TBL] [Abstract][Full Text] [Related]
30. Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.
Kiener R; Fleischmann M; Wiegand MA; Lemmermann NAW; Schwegler C; Kaufmann C; Renzaho A; Thomas S; Felder E; Niller HH; Asbach B; Wagner R
J Virol; 2018 Aug; 92(15):. PubMed ID: 29769344
[TBL] [Abstract][Full Text] [Related]
31. Comparison of vaccine strategies against congenital CMV infection in the guinea pig model.
Schleiss MR
J Clin Virol; 2008 Mar; 41(3):224-30. PubMed ID: 18060834
[TBL] [Abstract][Full Text] [Related]
32. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
Cui X; Cao Z; Wang S; Lee RB; Wang X; Murata H; Adler SP; McVoy MA; Snapper CM
Vaccine; 2018 Sep; 36(37):5580-5590. PubMed ID: 30082162
[TBL] [Abstract][Full Text] [Related]
33. DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice.
Gallez-Hawkins G; Li X; Franck AE; Thao L; Lacey SF; Diamond DJ; Zaia JA
Vaccine; 2004 Dec; 23(6):819-26. PubMed ID: 15542207
[TBL] [Abstract][Full Text] [Related]
34. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
[TBL] [Abstract][Full Text] [Related]
36. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.
Gil A; Shen S; Coley S; Gibson L; Diamond DJ; Wang S; Lu S
Hum Vaccin Immunother; 2013 Oct; 9(10):2120-32. PubMed ID: 24051429
[TBL] [Abstract][Full Text] [Related]
37. Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
Baraniak I; Kropff B; Ambrose L; McIntosh M; McLean GR; Pichon S; Atkinson C; Milne RSB; Mach M; Griffiths PD; Reeves MB
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):6273-6278. PubMed ID: 29686064
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65.
Vaz-Santiago J; Lulé J; Rohrlich P; Jacquier C; Gibert N; Le Roy E; Betbeder D; Davignon JL; Davrinche C
J Virol; 2001 Sep; 75(17):7840-7. PubMed ID: 11483727
[TBL] [Abstract][Full Text] [Related]
39. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
[TBL] [Abstract][Full Text] [Related]
40. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases.
Selinsky C; Luke C; Wloch M; Geall A; Hermanson G; Kaslow D; Evans T
Hum Vaccin; 2005; 1(1):16-23. PubMed ID: 17038834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
